Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in moderate to severe rheumatoid arthritis
NCT00083759Phase 2Terminated
- Sponsor
- Biogen
- Start
- May 2004
- Primary completion
- Feb 2005
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of natalizumab in rheumatoid arthritis (RA), sponsored by Biogen. Started May 2004; status: terminated.
02
Drugs
natalizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00083759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083759.